News

The two-period Phase III trial consisted of six months of on-demand therapy only, followed by 12 months of routine prophylaxis with BeneFIX 100 IU/kg once-weekly. The open-label, non-randomized

The trial will assess the safety, tolerability and pharmacokinetics of several oral formulations of ALKS 8700 compared to both placebo and active control groups in approximately 125 healthy

The trial would evaluate the safety and efficacy of ViaCyte’s VC-01 product candidate, a stem cell-derived, encapsulated cell replacement therapy. In a related development, ViaCyte submitted a Medical

The research and development program will focus on product candidates related to the inhibition of targets in the myostatin regulatory pathway as well as inflammatory mediators associated with

Top-line data from the trial, designated the ARM-TD (Aim to Reduce Movements in Tardive Dyskinesia) study, are expected in mid-2015. "Tardive dyskinesia is a side effect of certain

The invention relates to the company’s chimeric and codon-optimized flavivirus replicons, expression plasmids, and RVPs used for infectivity, neutralization, enhancement and structure-function studies of dengue virus (DENV) and

Currently, Eliquis is approved to reduce the risk of stroke and systemic embolism in patients with NVAF. Cardioversion is a commonly used, effective method of converting atrial fibrillation

Tarextumab is being tested in combination with Abraxane(R) (paclitaxel protein-bound particles for injectable suspension) (albumin bound) plus gemcitabine in patients with previously untreated stage IV pancreatic cancer. The

Patients with high levels of Lp(a) have an increased risk of atherosclerosis, coronary heart disease, aortic stenosis, heart attack and stroke. ISIS-APO(a) is designed to reduce Lp(a) by